TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies - 11/08/11
, Meike Ressing, MD a, Jochem Koenig, PhD a, Martin C Abba, PhD b, Theodoros Agorastos, ProfMD c, Sylvia MF Brenna, PhD d, Marco Ciotti, MD e, BR Das, PhD f, Annarosa Del Mistro, MD g, Aleksandra Dybikowska, PhD h, Anna R Giuliano, ProfPhD i, Zivile Gudleviciene, MD j, Ulf Gyllensten, ProfPhD k, Andrea LF Haws, MD l, Aslaug Helland, MD m, C Simon Herrington, ProfMD n, Alan Hildesheim, PhD o, Olivier Humbey, PhD p, Sun H Jee, ProfPhD q, Jae Weon Kim, ProfMD r, Margaret M Madeleine, PhD s, Joseph Menczer, ProfMD t, Hextan YS Ngan, ProfMD u, Akira Nishikawa, MD v, Yoshimitsu Niwa, MD w, Rosemary Pegoraro, PhD x, MR Pillai, ProfPhD y, Gulielmina Ranzani, ProfPhD z, Giovanni Rezza, MD aa, Adam N Rosenthal, MD ab, Susanta Roychoudhury, PhD ac, Dhananjaya Saranath, PhD ad, Virginia M Schmitt, ProfPhD ae, Sharmila Sengupta, ProfPhD af, Wannapa Settheetham-Ishida, PhD ag, Hiroshi Shirasawa, ProfPhD ah, Peter JF Snijders, ProfPhD ai, Mark H Stoler, ProfMD aj, Angel E Suárez-Rincón, MD ak, Krisztina Szarka, PhD al, Ruth Tachezy, PhD am, Masatsugu Ueda, MD an, Ate GJ van der Zee, ProfMD ao, Magnus von Knebel Doeberitz, ProfMD ap, Ming-Tsang Wu, ProfMD aq, Tsuyoshi Yamashita, MD ar, Ingeborg Zehbe, PhD as, Maria Blettner, ProfPhD aSummary |
Background |
Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.
Methods |
Individual data on 7946 cases and 7888 controls from 49 different studies worldwide were reanalysed. Odds ratios (OR) were estimated using logistic regression, stratifying by study and ethnic origin. Subgroup analyses were done for infection with HPV, ethnic origin, Hardy–Weinberg equilibrium, study quality, and the material used to determine TP53 genotype.
Findings |
The pooled estimates (OR) for invasive cervical cancer were 1·22 (95% CI 1·08–1·39) for arginine homozygotes compared with heterozygotes, and 1·13 (0·94–1·35) for arginine homozygotes versus proline homozygotes. Subgroup analyses showed significant excess risks only in studies where controls were not in Hardy–Weinberg equilibrium (1·71 [1·21–2·42] for arginine homozygotes compared with heterozygotes), in non-epidemiological studies (1·35 [1·15–1·58] for arginine homozygotes compared with heterozygotes), and in studies where TP53 genotype was determined from tumour tissue (1·39 [1·13–1·73] for arginine homozygotes compared with heterozygotes). Null results were noted in studies with sound epidemiological design and conduct (1·06 [0·87–1·29] for arginine homozygotes compared with heterozygotes), and studies in which TP53 genotype was determined from white blood cells (1·06 [0·87–1·29] for arginine homozygotes compared with heterozygotes).
Interpretation |
Subgroup analyses indicated that excess risks were most likely not due to clinical or biological factors, but to errors in study methods. No association was found between cervical cancer and TP53 codon 72 polymorphism when the analysis was restricted to methodologically sound studies.
Funding |
German Research Foundation (DFG).
El texto completo de este artículo está disponible en PDF.Esquema
Vol 10 - N° 8
P. 772-784 - août 2009 Regresar al número
Artículo precedente
- An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
- Francien H van Nederveen, José Gaal, Judith Favier, Esther Korpershoek, Rogier A Oldenburg, Elly MCA de Bruyn, Hein FBM Sleddens, Pieter Derkx, Julie Rivière, Hilde Dannenberg, Bart-Jeroen Petri, Paul Komminoth, Karel Pacak, Wim CJ Hop, Patrick J Pollard, Massimo Mannelli, Jean-Pierre Bayley, Aurel Perren, Stephan Niemann, Albert A Verhofstad, Adriaan P de Bruïne, Eamonn R Maher, Frédérique Tissier, Tchao Méatchi, Cécile Badoual, Jérôme Bertherat, Laurence Amar, Despoina Alataki, Eric Van Marck, Francesco Ferrau, Jerney François, Wouter W de Herder, Mark-Paul FM Vrancken Peeters, Anne van Linge, Jacques WM Lenders, Anne-Paule Gimenez-Roqueplo, Ronald R de Krijger, Winand NM Dinjens
- Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
- Roger Stupp, Michael Mayer, Roger Kann, Walter Weder, Abderahim Zouhair, Daniel C Betticher, Arnaud D Roth, Rolf A Stahel, Sabine Balmer Majno, Solange Peters, Lorenz Jost, Markus Furrer, Sandra Thierstein, Ralph A Schmid, Shu-Fang Hsu-Schmitz, René-Olivier Mirimanoff, Hans-Beat Ris, Miklos Pless
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?